Improvement of dyslipidemia in OLETF rats by the prostaglandin I2 analog beraprost sodium

Prostaglandins and Other Lipid Mediators

Volumn 93, Issue 1-2, 2010, Pages 14-19

  Watanabe, Maho ^a   Nakashima, Hitoshi ^a   Ito, Kenji ^a   Miyake, Katsuhisa ^a   Saito, Takao ^a  

^a FUKUOKA UNIVERSITY   (Japan)

Author keywords

Beraprost sodium (BPS); Dyslipidemia; LETO rat; OLETF rat; Prostaglandin I2

Indexed keywords

ACYLGLYCEROL PALMITOYLTRANSFERASE; BERAPROST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; LIPOPROTEIN LIPASE; MESSENGER RNA; TRANSKETOLASE; TRIACYLGLYCEROL LIPASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHOLESTEROL SYNTHESIS; CONTROLLED STUDY; DRUG DOSE COMPARISON; DYSLIPIDEMIA; ENZYME ACTIVITY; GENE EXPRESSION; KIDNEY; LIPID METABOLISM; LIVER; MALE; NONHUMAN; OSMOTIC PUMP; OTSUKA LONG EVANS TOKUSHIMA FATTY RAT; PENTOSE PHOSPHATE CYCLE; RAT; REAL TIME POLYMERASE CHAIN REACTION;

ACYLTRANSFERASES; ANIMALS; DYSLIPIDEMIAS; EPOPROSTENOL; HYDROXYMETHYLGLUTARYL COA REDUCTASES; LIPID METABOLISM; MALE; RATS; RATS, INBRED OLETF; TRANSKETOLASE; TRIGLYCERIDES;

EID: 77955417070     PISSN: 10988823     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.prostaglandins.2010.04.003     Document Type: Article

References (29)

1. Watanabe M., Nakashima H., Mochizuki S., et al. Amelioration of diabetic nephropathy in oletf rats by prostaglandin i(2) analog, beraprost sodium. Am J Nephrol 2009, 30:1-11.
2. Kawano K., Hirashima T., Mori S., et al. Spontaneous long-term hyperglycemic rat with diabetic complications. Otsuka Long-Evans Tokushima Fatty (oletf) strain. Diabetes 1992, 41:1422-1428.
3. Mochizuki S., Moriya T., Naganuma H., et al. Significance of fat stains in serial sections from epon-embedded tissue samples for electron microscopy in renal diseases. Clin Exp Nephrol 2001, 4:240-245.
4. Brown M.S., Goldstein J.L. Lipoprotein metabolism in the macrophage: Implications for cholesterol deposition in atherosclerosis. Annu Rev Biochem 1983, 52:223-261.
5. Kodama T., Freeman M., Rohrer L., et al. Type i macrophage scavenger receptor contains alpha-helical and collagen-like coiled coils. Nature 1990, 343:531-535.
6. Naito M., Suzuki H., Mori T., et al. Coexpression of type i and type ii human macrophage scavenger receptors in macrophages of various organs and foam cells in atherosclerotic lesions. Am J Pathol 1992, 141:591-599.
7. Steinberg D., Parthasarathy S., Carew T.E., et al. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989, 320:915-924.
8. Krieger M., Herz J. Structures and functions of multiligand lipoprotein receptors: macrophage scavenger receptors and ldl receptor-related protein (lrp). Annu Rev Biochem 1994, 63:601-637.
9. Rohrer L., Freeman M., Kodama T., et al. Coiled-coil fibrous domains mediate ligand binding by macrophage scavenger receptor type ii. Nature 1990, 343:570-572.
10. Vaziri N.D., Liang K.H. Hepatic hmg-coa reductase gene expression during the course of puromycin-induced nephrosis. Kidney Int 1995, 48:1979-1985.
11. Mishima K., Baba A., Matsuo M., et al. Protective effect of cyclic amp against cisplatin-induced nephrotoxicity. Free Radic Biol Med 2006, 40:1564-1577.
12. Nishikawa T., Edelstein D., Du X.L., et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 2000, 404:787-790.
13. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001, 414:813-820.
14. Du X.L., Edelstein D., Rossetti L., et al. Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing sp1 glycosylation. Proc Natl Acad Sci USA 2000, 97:12222-12226.
15. Brownlee M., Cerami A., Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 1988, 318:1315-1321.
16. Makita Z., Vlassara H., Rayfield E., et al. Hemoglobin-age: a circulating marker of advanced glycosylation. Science 1992, 258:651-653.
17. Hammes H.P., Du X., Edelstein D., et al. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat Med 2003, 9:294-299.
18. Stracke H., Hammes H.P., Werkmann D., et al. Efficacy of benfotiamine versus thiamine on function and glycation products of peripheral nerves in diabetic rats. Exp Clin Endocrinol Diabetes 2001, 109:330-336.
19. La Selva M., Beltramo E., Pagnozzi F., et al. Thiamine corrects delayed replication and decreases production of lactate and advanced glycation end-products in bovine retinal and human umbilical vein endothelial cells cultured under high glucose conditions. Diabetologia 1996, 39:1263-1268.
20. Babaei-Jadidi R., Karachalias N., Ahmed N., et al. Prevention of incipient diabetic nephropathy by high-dose thiamine and benfotiamine. Diabetes 2003, 52:2110-2120.
21. Babaei-Jadidi R., Karachalias N., Kupich C., et al. High-dose thiamine therapy counters dyslipidaemia in streptozotocin-induced diabetic rats. Diabetologia 2004, 47:2235-2246.
22. Thornalley P.J. The potential role of thiamine (vitamin b1) in diabetic complications. Curr Diabetes Rev 2005, 1:287-298.
23. Naveed A.K., Qamar T., Ahmad I., et al. Effect of thiamine on lipid profile in diabetic rats. J Coll Physicians Surg Pak 2009, 19:165-168.
24. Platt N., Gordon S. Is the class a macrophage scavenger receptor (sr-a) multifunctional?-the mouse's tale. J Clin Invest 2001, 108:649-654.
25. Santiago-Garcia J., Kodama T., Pitas R.E. The class a scavenger receptor binds to proteoglycans and mediates adhesion of macrophages to the extracellular matrix. J Biol Chem 2003, 278:6942-6946.
26. Coller S.P., Paulnock D.M. Signaling pathways initiated in macrophages after engagement of type a scavenger receptors. J Leukoc Biol 2001, 70:142-148.
27. Suzuki H., Kurihara Y., Takeya M., et al. A role for macrophage scavenger receptors in atherosclerosis and susceptibility to infection. Nature 1997, 386:292-296.
28. de Winther M.P., van Dijk K.W., Havekes L.M., et al. Macrophage scavenger receptor class a: a multifunctional receptor in atherosclerosis. Arterioscler Thromb Vasc Biol 2000, 20:290-297.
29. Uesugi N., Sakata N., Horiuchi S., et al. Glycoxidation-modified macrophages and lipid peroxidation products are associated with the progression of human diabetic nephropathy. Am J Kidney Dis 2001, 38:1016-1025.